In addition, we also found that a set of 730 CpG sites located within the epi-driver genes had the same direction of change for three or more cancer subtypes, including genes that had previously proved to have biological functions in cancer progression such as EGFR (Forloni et al., 2016; Apicella et al., 2018), NCOR2 (Bhasin et al., 2015), MAML3 (Sanchez-Vega et al., 2018), TSC2 (Papp et al., 2018), and FGFR2 (Roy et al., 2021) (Supplementary Table S3). This evidence concerns the gene EGFR and cancer.